Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYRRHINIL-INTEST versus placebo for diarrhoea-predominant irritable bowel syndrome
2024-514383-61-00Phase 4Authorised
- Sponsor
- Repha
- Start
- Jul 2020
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing MYRRHINIL-INTEST with Placebo (2 arms). Primary endpoint: Co-primary responder endpoint. Planned start Jul 2020; status: authorised.
02
Drugs
Myrrhinil-Intest
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2024-514383-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514383-61-00.